On this page
ACETYLCYSTEINE
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Antidote [EPC] | EPC | 6 members — no class page |
| Antidote for Acetaminophen Overdose [EPC] | EPC | 4 members — no class page |
| Decreased Respiratory Secretion Viscosity [PE] | PE | All 52 members |
| Increased Glutathione Concentration [PE] | PE | 4 members — no class page |
| Mucolytic [EPC] | EPC | 4 members — no class page |
| Reduction Activity [MoA] | MoA | 4 members — no class page |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 203853-001 | ACETYLCYSTEINE | SOLUTION | ACETYLCYSTEINE | Prescription | AN |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (aerosols)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | June 21, 2012 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260522). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE: Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)
INDICATIONS AND USAGE: Acetylcysteine Solution, USP administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. It is essential to initiate treatment as soon as possible after the overdose and, in any case, within 24 hours of ingestion.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION General Acetylcysteine Solution 10% and 20% is available in glass vials containing 30 mL. The 20% solution may be diluted to a lesser concentration with either Sodium Chloride Inhalation Solution; Sodium Chloride Injection; or Sterile Water for Injection, or Sterile Water for Inhalation. The 10% solution may be used undiluted. Storage of Opened Vials This product does not contain an antimicrobial agent, and care must be taken to minimize contamination of the sterile solution. If only a portion of the solution in a vial is used, store the remainder in a refrigerator and use for inhalation only within 96 hours. Nebulization — Face Mask, Mouth Piece, Tracheostomy When nebulized into a face mask, mouth piece or tracheostomy, 1 to 10 mL of the 20% solution or 2 to 20 mL of the 10% solution may be given every 2 to 6 hours; the recommended dose for most patients is 3 to 5 mL of the 20% solution or 6 to 10 mL of the 10% solution 3 to 4 times a day. Nebulization — Tent, Croupette In special circumstances it may be necessary to nebulize into a tent or Croupette, and this method of use must be individualized to take into account the available equipment and the patient's particular needs. This form of administration requires very large volumes of the solution, occasionally as much as 300 mL during a single treatment period. If a tent or Croupette must be used, the recommended dose is the volume of acetylcysteine (using 10% or 20%) that will maintain a very heavy mist in the tent or Croupette for the desired period. Administration for intermittent or continuous prolonged periods, including overnight, may be desirable. Direct Instillation When used by direct instillation, 1 to 2 mL of a 10% or 20% solution may be given as often as every hour. When used for the routine nursing care of patients with tracheostomy, 1 to 2 mL of a 10% to 20% solution may be given every 1 to 4 hours by instillation into the tracheostomy. Acetylcysteine may be introduced directly into a particular segment of the bronchopulmonary tree by inserting (under local anesthesia and direct vision) a small plastic catheter into the trachea. Two to 5 mL of the 20% solution may then be instilled by means of a syringe connected to the catheter. Acetylcysteine may also be given through a percutaneous intratracheal catheter. One to 2 mL of the 20% or 2 to 4 mL of the 10% solution every 1 to 4 hours may then be given by a syringe attached to the catheter. Diagnostic Bronchograms For diagnostic bronchial studies, 2 or 3 administrations of 1 to 2 mL of the 20% solution or 2 to 4 mL of the 10% solution should be given by nebulization or by instillation intratracheally, prior to the procedure. Administration of Aerosol Materials Acetylcysteine may be administered using conventional nebulizers made of plastic or glass. Certain materials used in nebulization equipment react with acetylcysteine. The most reactive of these are certain metals (notably iron and copper) and rubber. Where material may come into contact with acetylcysteine solution, parts made of the following acceptable materials should be used: glass, plastic, aluminum, anodized aluminum, chromed metal, tantalum, sterling silver, or stainless steel. Silver may become tarnished after exposure, but this is not harmful to the drug action or to the patient. Nebulizing Gases Compressed tank gas (air) or an air compressor should be used to provide pressure for nebulizing the solution. Oxygen may also be used but should be used with usual precautions in patients with severe respiratory disease and CO 2 retention. Apparatus Acetylcysteine is usually administered as fine nebulae, and the nebulizer used should be capable of providing optimal quantities of a suitable range of particle sizes. Commercially available nebulizers will produce nebulae of acetylcysteine satisfactory for retention in the respiratory tract. Most of the nebulizers tested will supply a high proportion of the drug solution as particles o …
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Acetylcysteine solution is contraindicated in those patients who are sensitive to it.
CONTRAINDICATIONS There are no contraindications to oral administration of acetylcysteine in the treatment of acetaminophen overdose.
Warnings
openFDA Drug LabelingWARNINGS After proper administration of acetylcysteine solution, an increased volume of liquified bronchial secretions may occur. When cough is inadequate, the airway must be maintained open by mechanical suction if necessary. Where there is a mechanical block due to foreign body or local accumulation, the airway should be cleared by endotracheal aspiration, with or without bronchoscopy. Asthmatics under treatment with acetylcysteine solution should be watched carefully. Most patients with bronchospasm are quickly relieved by the use of a bronchodilator given by nebulization. If bronchospasm progresses, the medication should be discontinued immediately.
WARNINGS Generalized urticaria has been observed rarely in patients receiving oral acetylcysteine for acetaminophen overdose. If this occurs or other allergic symptoms appear, treatment with acetylcysteine should be discontinued unless it is deemed essential and the allergic symptoms can be otherwise controlled. If encephalopathy due to hepatic failure becomes evident, acetylcysteine treatment should be discontinued to avoid further administration of nitrogenous substances. There are no data indicating that acetylcysteine influences hepatic failure, but this remains a theoretical possibility.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS: Adverse effects have included stomatitis, nausea, vomiting, fever, rhinorrhea, drowsiness, clamminess, chest tightness, and bronchoconstriction. Clinically overt acetylcysteine induced bronchospasm occurs infrequently and unpredictably even in patients with asthmatic bronchitis or bronchitis complicating bronchial asthma. Acquired sensitization to acetylcysteine has been reported rarely. Reports of sensitization in patients have not been confirmed by patch testing. Sensitization has been confirmed in several inhalation therapists who reported a history of dermal eruptions after frequent and extended exposure to acetylcysteine. Reports of irritation to the tracheal and bronchial tracts have been received and although hemoptysis has occurred in patients receiving acetylcysteine such findings are not uncommon in patients with bronchopulmonary disease and a causal relationship has not been established.
ADVERSE REACTIONS: Oral administration of acetylcysteine, especially in the large doses needed to treat acetaminophen overdose, may result in nausea, vomiting and other gastrointestinal symptoms. Rash with or without mild fever has been observed rarely.
Drug Interactions
openFDA Drug LabelingDrug Interactions Drug stability and safety of acetylcysteine when mixed with other drugs in a nebulizer have not been established.
Description
openFDA Drug LabelingDESCRIPTION Acetylcysteine solution is for inhalation (mucolytic agent) or oral administration (acetaminophen antidote), and available as sterile, unpreserved solutions (not for injection). Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°−110°C and has a very slight odor. The structural formula for acetylcysteine is as follows: Molecular weight: 163.19 Each mL of the 10% solution contains acetylcysteine 100 mg; edetate disodium, dihydrate 0.25 mg. Each mL of the 20% solution contains acetylcysteine 200 mg; edetate disodium, dihydrate 0.5 mg. The solutions also contain sodium hydroxide and may contain hydrochloric acid for pH adjustment, pH 7.0 (6.0 to 7.5). Acetylcysteine Solution, USP is oxygen sensitive. Acetylcysteine As A Mucolytic Agent structural formula acetylcysteine
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Acetylcysteine Solution, USP is available in rubber stoppered glass vials containing 4, 10, or 30 mL. The 20% solution may be diluted to a lesser concentration with either Sodium Chloride for Injection, Sodium Chloride for Inhalation, Sterile Water for Injection, or Sterile Water for Inhalation. The 10% solution may be used undiluted. Acetylcysteine is sterile, not for injection and can be used for inhalation (mucolytic agent) or oral administration (acetaminophen antidote). It is available as follows: Acetylcysteine 10% solution (100 mg acetylcysteine per mL). Sterile, not for injection. Product No. NDC No. Strength 695104 63323-695-04 10% (100 mg/mL) 4 mL 5 mL vials packed in carton of twenty five 693110 63323-693-10 10% (100 mg/mL) 10 mL 10 mL vials packed in carton of three, plastic dropper 691130 63323-691-30 10% (100 mg/mL) 30 mL 30 mL vials packed in carton of three Acetylcysteine 20% solution (200 mg acetylcysteine per mL). Sterile, not for injection. Product No. NDC No. Strength 694104 63323-694-04 20% (200 mg/mL) 4 mL 5 mL vials packed in carton of twenty five 692110 63323-692-10 20% (200 mg/mL) 10 mL 10 mL vials packed in carton of three, plastic dropper 690130 63323-690-30 20% (200 mg/mL) 30 mL 30 mL vials packed in carton of three STORAGE: Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (see USP Controlled Room Temperature). Store in refrigerator 2° - 8°C (36° - 46°F) after opening. Acetylcysteine does not contain an antimicrobial agent, and care must be taken to minimize contamination of the sterile solution. Dilutions of acetylcysteine should be used freshly prepared and utilized within one hour. If only a portion of the solution in a vial is used, store the remaining undiluted portion in a refrigerator and use within 96 hours.
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: ACETYLCYSTEINE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 42494-435-25 | 42494-435 | Cameron Pharmaceuticals | 25 VIAL in 1 CARTON (42494-435-25) / 4 mL in 1 VIAL | August 21, 2025 |
| 42494-436-25 | 42494-436 | Cameron Pharmaceuticals | 25 VIAL in 1 CARTON (42494-436-25) / 4 mL in 1 VIAL | August 21, 2025 |
| 63323-690-30 | 63323-690 | Fresenius Kabi USA, LLC | 3 VIAL in 1 CARTON (63323-690-30) / 30 mL in 1 VIAL (63323-690-22) | September 1, 2012 |
| 63323-690-44 | 63323-690 | Fresenius Kabi USA, LLC | 3 VIAL in 1 CARTON (63323-690-44) / 30 mL in 1 VIAL (63323-690-41) | September 1, 2012 |
| 63323-691-30 | 63323-691 | Fresenius Kabi USA, LLC | 3 VIAL in 1 CARTON (63323-691-30) / 30 mL in 1 VIAL (63323-691-22) | March 31, 2014 |
| 63323-692-10 | 63323-692 | Fresenius Kabi USA, LLC | 3 VIAL in 1 CARTON (63323-692-10) / 10 mL in 1 VIAL (63323-692-22) | September 1, 2012 |
| 63323-693-10 | 63323-693 | Fresenius Kabi USA, LLC | 3 VIAL in 1 CARTON (63323-693-10) / 10 mL in 1 VIAL (63323-693-22) | March 31, 2014 |
| 63323-694-04 | 63323-694 | Fresenius Kabi USA, LLC | 25 VIAL in 1 CARTON (63323-694-04) / 4 mL in 1 VIAL (63323-694-22) | September 1, 2012 |
| 63323-694-44 | 63323-694 | Fresenius Kabi USA, LLC | 25 VIAL in 1 CARTON (63323-694-44) / 4 mL in 1 VIAL (63323-694-41) | September 1, 2012 |
| 63323-695-04 | 63323-695 | Fresenius Kabi USA, LLC | 25 VIAL in 1 CARTON (63323-695-04) / 4 mL in 1 VIAL (63323-695-22) | March 31, 2014 |
| 0409-3307-03 | 0409-3307 | Hospira, Inc. | 3 VIAL in 1 CARTON (0409-3307-03) / 30 mL in 1 VIAL (0409-3307-11) | April 30, 2005 |
| 0409-3308-03 | 0409-3308 | Hospira, Inc. | 3 VIAL in 1 CARTON (0409-3308-03) / 30 mL in 1 VIAL (0409-3308-11) | June 1, 2005 |
| 70069-018-25 | 70069-018 | Somerset Therapeutics, LLC | 25 VIAL in 1 CARTON (70069-018-25) / 4 mL in 1 VIAL (70069-018-01) | March 4, 2025 |
| 70069-019-25 | 70069-019 | Somerset Therapeutics, LLC | 25 VIAL in 1 CARTON (70069-019-25) / 4 mL in 1 VIAL (70069-019-01) | March 4, 2025 |
| 70069-020-03 | 70069-020 | Somerset Therapeutics, LLC | 3 VIAL in 1 CARTON (70069-020-03) / 30 mL in 1 VIAL (70069-020-01) | March 4, 2025 |
| 42494-435 | 42494-435 | Cameron Pharmaceuticals | — | August 21, 2025 |
| 42494-436 | 42494-436 | Cameron Pharmaceuticals | — | August 21, 2025 |
| 63323-690 | 63323-690 | Fresenius Kabi USA, LLC | — | September 1, 2012 |
| 63323-691 | 63323-691 | Fresenius Kabi USA, LLC | — | March 31, 2014 |
| 63323-692 | 63323-692 | Fresenius Kabi USA, LLC | — | September 1, 2012 |
| 63323-693 | 63323-693 | Fresenius Kabi USA, LLC | — | March 31, 2014 |
| 63323-694 | 63323-694 | Fresenius Kabi USA, LLC | — | September 1, 2012 |
| 63323-695 | 63323-695 | Fresenius Kabi USA, LLC | — | March 31, 2014 |
| 0409-3307 | 0409-3307 | Hospira, Inc. | — | April 30, 2005 |
| 0409-3308 | 0409-3308 | Hospira, Inc. | — | June 1, 2005 |
| 70069-018 | 70069-018 | Somerset Therapeutics, LLC | — | March 4, 2025 |
| 70069-019 | 70069-019 | Somerset Therapeutics, LLC | — | March 4, 2025 |
| 70069-020 | 70069-020 | Somerset Therapeutics, LLC | — | March 4, 2025 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.